DK172794B1 - Farmaceutisk melphalanpræparat, fremgangsmåde til fremstilling heraf og fremgangsmåde til fremstilling af i det væsentlige - Google Patents

Farmaceutisk melphalanpræparat, fremgangsmåde til fremstilling heraf og fremgangsmåde til fremstilling af i det væsentlige Download PDF

Info

Publication number
DK172794B1
DK172794B1 DK198806466A DK646688A DK172794B1 DK 172794 B1 DK172794 B1 DK 172794B1 DK 198806466 A DK198806466 A DK 198806466A DK 646688 A DK646688 A DK 646688A DK 172794 B1 DK172794 B1 DK 172794B1
Authority
DK
Denmark
Prior art keywords
melphalan
hydrochloride
preparation
component
citrate
Prior art date
Application number
DK198806466A
Other languages
Danish (da)
English (en)
Other versions
DK646688A (da
DK646688D0 (da
Inventor
Stephen William Poole
Timothy Paul Stanley
Geoffrey Divall
Terence William Packham
Joseph Knight
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of DK646688D0 publication Critical patent/DK646688D0/da
Publication of DK646688A publication Critical patent/DK646688A/da
Application granted granted Critical
Publication of DK172794B1 publication Critical patent/DK172794B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
DK198806466A 1987-11-19 1988-11-18 Farmaceutisk melphalanpræparat, fremgangsmåde til fremstilling heraf og fremgangsmåde til fremstilling af i det væsentlige DK172794B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878727157A GB8727157D0 (en) 1987-11-19 1987-11-19 Pharmaceutical formulations
GB8727157 1987-11-19

Publications (3)

Publication Number Publication Date
DK646688D0 DK646688D0 (da) 1988-11-18
DK646688A DK646688A (da) 1989-05-20
DK172794B1 true DK172794B1 (da) 1999-07-19

Family

ID=10627252

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198806466A DK172794B1 (da) 1987-11-19 1988-11-18 Farmaceutisk melphalanpræparat, fremgangsmåde til fremstilling heraf og fremgangsmåde til fremstilling af i det væsentlige

Country Status (22)

Country Link
US (1) US4997651A (fr)
EP (1) EP0317281B1 (fr)
JP (1) JP2693191B2 (fr)
KR (1) KR970002607B1 (fr)
AT (1) ATE83922T1 (fr)
AU (1) AU619781B2 (fr)
CA (1) CA1341114C (fr)
DE (1) DE3877151T2 (fr)
DK (1) DK172794B1 (fr)
ES (1) ES2052745T3 (fr)
FI (2) FI90204C (fr)
GB (1) GB8727157D0 (fr)
GR (1) GR3007287T3 (fr)
HK (1) HK108994A (fr)
HU (3) HU206671B (fr)
IE (1) IE63996B1 (fr)
IL (1) IL88419A (fr)
LV (1) LV10179B (fr)
NZ (2) NZ227004A (fr)
PT (1) PT89028B (fr)
SG (1) SG73894G (fr)
ZA (1) ZA888674B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695751A (en) * 1993-04-08 1997-12-09 Cornell Research Foundation, Inc. Enhancing delivery of large neutral amino acid drugs
US5407672A (en) * 1993-04-08 1995-04-18 Cornell Research Foundation, Inc. Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US5980904A (en) * 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
AU2003253681B2 (en) * 2002-06-24 2008-05-01 Research Development Foundation Treatment of human multiple myeloma by Curcumin
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
LT3494960T (lt) 2008-03-27 2021-02-25 Helsinn Healthcare Sa Stabilizuotos alkilinimo agentų kompozicijos ir jų naudojimo būdai
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CN102458114A (zh) * 2009-05-29 2012-05-16 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
AR077384A1 (es) * 2010-07-05 2011-08-24 Eriochem Sa Una formulacion farmaceutica inyectable de melfalano.
US8921596B2 (en) * 2010-11-04 2014-12-30 Emcure Pharmaceuticals, Ltd. Process for the preparation of melphalan hydrochloride
PL3656393T3 (pl) 2011-04-28 2023-01-16 Oncopeptides Ab Liofilizowany preparat cytotoksycznych dipeptydów
SI2928463T1 (sl) * 2012-10-26 2020-03-31 Oncopeptides Ab Liofilizirani pripravki melfalan flufenamida
US9963422B2 (en) 2013-03-11 2018-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of melphalan and the hydrochloride salt
ITMI20130896A1 (it) * 2013-05-31 2014-12-01 Farmabios Spa Processo di purificazione di melphalan
US10576101B2 (en) * 2015-03-06 2020-03-03 Leadiant Biosciences Sa Roneparstat combined therapy of multiple myeloma
US10537520B2 (en) * 2015-06-30 2020-01-21 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan
ES2928931T3 (es) * 2018-03-29 2022-11-23 Project Pharmaceutics Gmbh Formulación farmacéutica líquida
US10682326B1 (en) 2019-06-03 2020-06-16 Shilpa Medicare Limited Stable melphalan liquid injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
DE1292660B (de) * 1963-04-24 1969-04-17 Ural Polytechnitscheskij I Im Verfahren zur Herstellung von p-(Bis-ª‰-chloraethyl-amino)-phenylalanin-hydrochlorid
US4029778A (en) * 1969-01-23 1977-06-14 Aktiebolaget Leo Cortical steroid nitrogen mustard compositions and treatment therewith
RO57195A2 (fr) * 1970-11-30 1974-09-01
FR2285855A1 (fr) * 1974-09-25 1976-04-23 Kohjin Co Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
JPS62192357A (ja) * 1986-02-19 1987-08-22 Kureha Chem Ind Co Ltd Ｎ−フタロイル−ｐ−ニトロ−Ｌ−フエニルアラニンの製造方法

Also Published As

Publication number Publication date
US4997651A (en) 1991-03-05
NZ239867A (en) 1992-11-25
IE883447L (en) 1989-05-19
HUT48198A (en) 1989-05-29
GR3007287T3 (fr) 1993-07-30
DK646688A (da) 1989-05-20
IL88419A0 (en) 1989-06-30
HU203197B (en) 1991-06-28
DE3877151D1 (de) 1993-02-11
FI885358A0 (fi) 1988-11-18
SG73894G (en) 1994-11-25
FI90204C (fi) 1994-01-10
FI102275B1 (fi) 1998-11-13
EP0317281B1 (fr) 1992-12-30
JP2693191B2 (ja) 1997-12-24
FI102275B (fi) 1998-11-13
KR970002607B1 (ko) 1997-03-06
IE63996B1 (en) 1995-06-28
EP0317281A2 (fr) 1989-05-24
LV10179A (lv) 1994-10-20
EP0317281A3 (en) 1989-08-09
FI924668A (fi) 1992-10-15
GB8727157D0 (en) 1987-12-23
HU9100335D0 (en) 1991-08-28
KR890007729A (ko) 1989-07-05
HU206671B (en) 1992-12-28
AU619781B2 (en) 1992-02-06
PT89028B (pt) 1993-02-26
PT89028A (pt) 1988-12-01
AU2574888A (en) 1989-05-25
NZ227004A (en) 1992-11-25
CA1341114C (fr) 2000-10-10
HK108994A (en) 1994-10-14
JPH01153628A (ja) 1989-06-15
LV10179B (en) 1995-06-20
ATE83922T1 (de) 1993-01-15
ES2052745T3 (es) 1994-07-16
IL88419A (en) 1993-03-15
DK646688D0 (da) 1988-11-18
HU910336D0 (en) 1991-08-28
FI924668A0 (fi) 1992-10-15
ZA888674B (en) 1990-07-25
FI885358A (fi) 1989-05-20
FI90204B (fi) 1993-09-30
HU207286B (en) 1993-03-29
DE3877151T2 (de) 1993-07-15

Similar Documents

Publication Publication Date Title
DK172794B1 (da) Farmaceutisk melphalanpræparat, fremgangsmåde til fremstilling heraf og fremgangsmåde til fremstilling af i det væsentlige
JP3803392B2 (ja) 環式付着阻害剤
CA2849456A1 (fr) Methodes de traitement de maladies
JPH02306921A (ja) 安定化されたカルシトニン類医薬組成物
JP2004512339A (ja) 抗菌化合物を配合する方法
RU2272623C2 (ru) РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ
JPS62149621A (ja) ホスホクレアチン含有薬剤及びそれを製造する方法
BE1001704A3 (fr) Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique.
JP2003514779A (ja) カルバペネム系抗生物質組成物の処方方法
HU191538B (en) Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres
CN108289897B (zh) 一种瑞马唑仑的药物组合物
JP4130700B2 (ja) 抗腫瘍剤含有組成物
CZ8095A3 (en) Hydrochloride of ng-monomethyl-l-arginine, process of its preparation, pharmaceutical composition containing thereof and its use in medicine
JP3956654B2 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
PH26521A (en) Pharmaceutical formulation
WO2024179577A1 (fr) Composition pharmaceutique pour agent de dégradation de protéines de la famille bcl-2
US4322424A (en) Crystalline glucoconate salt of m-AMSA and compositions containing same
JPS6165819A (ja) 有機ゲルマニウム化合物を含有する薬剤組成物
JPS63174927A (ja) 抗菌性凍結乾燥製剤
KR810002136B1 (ko) 아목시실린 나트륨 함유 주사용 약제조성물의 제조방법
KR830000525B1 (ko) 주사용 아세틸 살리실레이트 분말제의 안정화 방법
JP2022509904A (ja) トレオスルファンの凍結乾燥物
JP2022509905A (ja) トレオスルファンの結晶形
GB1582207A (en) Stable isosorbide dinitrate solutions preparation thereof and use thereof
JPS62187410A (ja) Ａｔｐ増強組成物

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired